163 related articles for article (PubMed ID: 35972237)
1. Understanding the Mechanism of Drug Transfer and Retention of Drug-Coated Balloons.
Villar-Matamoros E; Stokes L; Lloret A; Todd M; Tillman BW; Yazdani SK
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221119559. PubMed ID: 35972237
[TBL] [Abstract][Full Text] [Related]
2. Development of drug-coated balloon for the treatment of multiple peripheral artery segments.
Anderson JA; Lamichhane S; Fuglsby K; Remund T; Pohlson K; Evans R; Engebretson D; Kelly P
J Vasc Surg; 2020 May; 71(5):1750-1757.e7. PubMed ID: 31519510
[TBL] [Abstract][Full Text] [Related]
3. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
[TBL] [Abstract][Full Text] [Related]
4. Coating and Pharmacokinetic Evaluation of Air Spray Coated Drug Coated Balloons.
Turner EA; Atigh MK; Erwin MM; Christians U; Yazdani SK
Cardiovasc Eng Technol; 2018 Jun; 9(2):240-250. PubMed ID: 29497966
[TBL] [Abstract][Full Text] [Related]
5. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model.
Yazdani SK; Pacheco E; Nakano M; Otsuka F; Naisbitt S; Kolodgie FD; Ladich E; Rousselle S; Virmani R
Catheter Cardiovasc Interv; 2014 Jan; 83(1):132-40. PubMed ID: 23703778
[TBL] [Abstract][Full Text] [Related]
6. Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons.
Goel E; Erwin M; Cawthon CV; Schaff C; Fedor N; Rayl T; Wilson O; Christians U; Register TC; Geary RL; Saul J; Yazdani SK
Molecules; 2020 Mar; 25(7):. PubMed ID: 32244375
[TBL] [Abstract][Full Text] [Related]
7. An Experimental Study of Paclitaxel Embolisation During Drug Coated Balloon Angioplasty.
Boitet A; Grassin-Delyle S; Louedec L; Dupont S; Lamy E; Coggia M; Michel JB; Coscas R
Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):578-586. PubMed ID: 30871939
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
[TBL] [Abstract][Full Text] [Related]
9. Drug loss from Paclitaxel-Coated Balloons During Preparation, Insertion and Inflation for Angioplasty: A Laboratory Investigation.
Faenger B; Heinrich A; Hilger I; Teichgräber U
Cardiovasc Intervent Radiol; 2022 Aug; 45(8):1186-1197. PubMed ID: 35689119
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
[No Abstract] [Full Text] [Related]
11. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
12. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
[TBL] [Abstract][Full Text] [Related]
13. Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis.
Gurin MI; Beyer SE; Weinberg M; Parikh SA; Armstrong EJ; Albaghdadi MS; Aronow HD; Carroll BJ; Yeh R; Secemsky EA
J Endovasc Ther; 2021 Apr; 28(2):246-254. PubMed ID: 33426984
[TBL] [Abstract][Full Text] [Related]
14. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
Herten M; Torsello GB; Schönefeld E; Stahlhoff S
Vasc Health Risk Manag; 2016; 12():341-56. PubMed ID: 27621646
[TBL] [Abstract][Full Text] [Related]
15. In vitro particulate and in vivo drug retention study of a novel polyethylene oxide formulation for drug-coated balloons.
Anderson JA; Lamichhane S; Vierhout T; Sherman A; Engebretson D; Pohlson K; Remund T; Kelly P
J Vasc Surg; 2018 May; 67(5):1537-1545.e7. PubMed ID: 28843789
[TBL] [Abstract][Full Text] [Related]
16. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
[TBL] [Abstract][Full Text] [Related]
18. Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
Brodmann M; Werner M; Meyer DR; Reimer P; Krüger K; Granada JF; Jaff MR; Schroeder H;
JACC Cardiovasc Interv; 2018 Dec; 11(23):2357-2364. PubMed ID: 30522663
[TBL] [Abstract][Full Text] [Related]
19. Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon.
Schneider PA; Laird JR; Doros G; Gao Q; Ansel G; Brodmann M; Micari A; Shishehbor MH; Tepe G; Zeller T
J Am Coll Cardiol; 2019 May; 73(20):2550-2563. PubMed ID: 30690141
[TBL] [Abstract][Full Text] [Related]
20. The Ranger drug-coated balloon: advances in drug-coated technology for treatment of femoropopliteal segment arterial disease.
Sharma N; Finn MT; Parikh SA; Granada J
Future Cardiol; 2023 Mar; 19(3):127-135. PubMed ID: 37334764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
